Jones CM - Thalidomide, a drug once thought to have no clinical benefit due to its significant toxicity, has now become a potential agent for the treatment of hematologic malignancies and some solid tumors. Thalidomide in combination with dexamethasone is approved for use in multiple myeloma. Current study data show promising results for hepatocellular carcinoma, prostate, neuroendocrine, and ovarian cancers, but larger studies are needed to fully define the role of thalidomide in these cancers.
See all
